ゴリムマブ（遺伝子組換え）
ゴリムマブ（遺伝子組換え） 物理性質
- 貯蔵温度 :
- Store at -20°C
- 外見 :
- Liquid
- 色:
- Colorless to light yellow
安全性情報
- リスクと安全性に関する声明
- 危険有害性情報のコード(GHS)
| 絵表示（GHS） |
|
| 注意喚起語 |
|
| 危険有害性情報 |
| コード |
危険有害性情報 |
危険有害性クラス |
区分 |
注意喚起語 |
シンボル |
P コード |
| H334 |
吸入するとアレルギー、喘息または、呼吸困難 を起こすおそれ |
感作性、呼吸器 |
1 |
危険 |
|
P261, P285, P304+P341, P342+P311,P501 |
|
| 注意書き |
| P261 |
粉じん/煙/ガス/ミスト/蒸気/スプレーの吸入を避ける こと。 |
| P285 |
換気が十分でない場合には、呼吸用保護具を着用する こと。 |
| P304+P341 |
吸入した場合：呼吸が困難な場合には、空気の新鮮な場 所に移し、呼吸しやすい姿勢で休息させること。 |
| P342+P311 |
呼吸に関する症状が出た場合：医師に連絡すること。 |
| P501 |
内容物/容器を．．．に廃棄すること。 |
|
ゴリムマブ（遺伝子組換え） 価格
| メーカー |
製品番号 |
製品説明 |
CAS番号 |
包装 |
価格 |
更新時間 |
購入 |
ゴリムマブ（遺伝子組換え） 化学特性,用途語,生産方法
説明
The proinflammatory cytokine tumor necrosis factor-alpha (TNF-α) has
been implicated as the primary mediator of articular inflammation in
diseases such as RA, PsA, and AS. Targeting TNF-a has been a successful
strategy in the intervention of a range of immunoinflammatory disorders.
Biologics have risen to the forefront of TNF-α blockade with infliximab, a
chimeric monoclonal antibody (mAb), and etanercept, a fusion protein
comprised of the ligand-binding segment of the soluble TNF receptor,
reaching the market in the late 1990s for the initial indication of RA. Since
then, their use has expanded to other diseases of inflammatory etiology,
and two additional TNF-α inhibitors have joined the competition.
Golimumab, a
human anti-TNF-α mAb that binds to both soluble and transmembrane
forms of TNF-a, is the first once-monthly subcutaneous agent to enter the
market and is currently approved for the treatment of RA in combination
with methotrexate (MTX), PsA alone or in combination with MTX, and AS.
.
使用
Treatment of allergic asthma.
副作用
The most common adverse reactions,
occurring with an incidence >5%, were upper respiratory tract infection
and nasopharyngitis. Regarding drug interactions, live vaccines should not be administered while being treated with golimumab. As an increased
risk of serious infection has been associated with concomitant use
of abatacept and anakinra, combination of these drugs is not recommended.
Also, golimumab treatment should not be initiated in patients
with an active infection. Furthermore, patients should be warned about the
higher incidence of malignancies observed with anti-TNF-a therapy and
increased risks of worsening or new onset of heart failure, of exacerbation
or new onset of demyelinating disease, and of hepatitis B reactivation.
ゴリムマブ（遺伝子組換え） 上流と下流の製品情報
原材料
準備製品
ゴリムマブ（遺伝子組換え） 生産企業
Global( 15)Suppliers
476181-74-5(ゴリムマブ（遺伝子組換え）)キーワード:
- 476181-74-5
- CNTO 148
- Golimumab
- Simponi
- Research Grade Golimumab (DHB94404)
- Research Grade Golimumab
- MK-8259|||SCH 900259|||CNTO-148
- ゴリムマブ（遺伝子組換え）